Emcure Pharmaceuticals Share Price Target 2026: Stock Analysis, Share Price Today, Bull Case and Bear Case After Q1 FY27
- July 3, 2026
- Posted by: Kunal Singla
- Category: News
Emcure Pharmaceuticals Rs 1,933.70 (5 Oct 2026). 52-week range Rs 1,306.50 to Rs 2,100.70. Q1 FY27 PAT Rs 292.5 cr, up 36%. P/E 36.2x.
Quick Answer
The Emcure Pharmaceuticals share price target for 2026 is Rs 1,998 to Rs 2,294, which is 3 to 19 percent above the latest price of Rs 1,933.70, with bull and bear cases of Rs 2,666 to Rs 2,924 and Rs 1,488 to Rs 1,674. Emcure Pharmaceuticals reported Q1 FY27 revenue up 22.8 percent to Rs 2,580.4 crore and profit up 36.2 percent to Rs 292.5 crore, with international revenue up 34.2 percent and EBITDA margin up 50 basis points to 19.7 percent. Management guided to low to mid-teen revenue growth and a further 70 to 100 basis points of margin gain in FY27, and the stock is up about 44 percent in a year at 36.2 times earnings. No brokerage price target was available on the sources we track as of 5 October 2026, so every range below is a Univest research scenario.
The Emcure Pharmaceuticals share price target for 2026 is Rs 1,998 to Rs 2,294 in the Univest base case, with the stock at Rs 1,933.70 as of about 2:42 PM IST on 5 October 2026. That is 7.9 percent below its 52-week high of Rs 2,100.70 and 48.0 percent above its 52-week low of Rs 1,306.50, and the stock moved up 44.3 percent over the past year. Emcure Pharmaceuticals is a Pune-based pharma company with a strong India portfolio and an international business that is 58 percent of revenue. Net debt is about 0.6 times EBITDA and return on equity is 18.7 percent.
Three things changed since the last update: Q1 FY27 results on 6 August beat on profit, its semaglutide brand Poviztra gained a MASH indication, and the stock hit Rs 2,100.70 in the week of 14 September. This Emcure Pharmaceuticals stock analysis covers the Emcure Pharmaceuticals share price today, the Emcure Pharmaceuticals share price target for 2026, 2027 and 2030, the Q1 FY27 numbers, catalysts and risks, key price levels and a Emcure Pharmaceuticals buy or sell view.
Click Here – Get Free Investment Predictions
What Is the Emcure Pharmaceuticals Share Price Target for 2026?
The 2026 target for Emcure Pharmaceuticals shares is Rs 1,998 to Rs 2,294 in the Univest base case, which is +3.3% to +18.6% against the latest price. The bull case is Rs 2,666 to Rs 2,924 and the bear case is Rs 1,488 to Rs 1,674. No brokerage price target was available on the sources we track as of 5 October 2026, so every range below is a Univest research scenario. Analyst consensus is used as a cross-check, not as the base.
Emcure Pharmaceuticals Share Price Target Scenarios: Bull Case, Base Case and Bear Case
| Scenario | FY28E EPS | Target Multiple | Price Target (Rs) | Move vs Rs 1,933.70 |
|---|---|---|---|---|
| Bull Case | Rs 86 | 31x to 34x | 2,666 to 2,924 | +37.9% to +51.2% |
| Base Case | Rs 74 | 27x to 31x | 1,998 to 2,294 | +3.3% to +18.6% |
| Bear Case | Rs 62 | 24x to 27x | 1,488 to 1,674 | -23.0% to -13.4% |
FY28 EPS of Rs 74 in the base case is above trailing EPS of Rs 53.71 and the Q1 FY27 annualised figure of about Rs 61, assuming low to mid-teen revenue growth and margin gains of 70 to 100 basis points. The bull case needs semaglutide sales and international growth to stay strong, and the bear case assumes gross margin keeps falling. The PE multiple used for each case is shown in the table, and the EPS estimate is a Univest assumption, not company guidance. Those assumptions set the Emcure Pharmaceuticals share price target range around the current price.
Emcure Pharmaceuticals Company Overview and Share Price Today as of 5 October 2026
Emcure Pharmaceuticals share price today is Rs 1,933.70 on the NSE at about 2:42 PM IST on 5 October 2026, and it changes through the session. The market capitalisation is Rs 36,872 crore, and the stock trades at 36.2 times earnings, close to the industry average of 37.5 times. The Univest base case Emcure Pharmaceuticals share price target of Rs 1,998 to Rs 2,294 is +3.3% to +18.6% from here. The table below sets out the key numbers behind the Emcure Pharmaceuticals share price target.
| Parameter | Value | Context |
|---|---|---|
| NSE Ticker | EMCURE | BSE code 544210 |
| Sector | Pharmaceuticals | Per Univest sector classification |
| Latest Price (NSE) | Rs 1,933.70 | 5 Oct 2026, 2:42 PM IST |
| 52-Week High | Rs 2,100.70 | CMP is 7.9% below |
| 52-Week Low | Rs 1,306.50 | CMP is 48.0% above |
| 1-Year Return | About +44% | Weekly close Rs 1,339.90 on 3 Oct 2025 to Rs 1,932.90 |
| Market Capitalisation | Rs 36,872 crore | Mid cap pharma company |
| Trailing P/E | About 36.2x | Industry P/E about 37.5x |
| P/B Ratio | About 7.45x | Book value Rs 260.93 per share |
| EPS (TTM) | Rs 53.71 | Trailing twelve months |
| Return on Equity | About 18.7% | Debt to equity 0.31 |
| Dividend Yield | About 0.19% | Small dividend |
| 12-Month Target (Base Case) | Rs 1,998 to Rs 2,294 | Univest base case |
| Bull Case | Rs 2,666 to Rs 2,924 | +37.9% to +51.2% |
| Bear Case | Rs 1,488 to Rs 1,674 | -23.0% to -13.4% |
Track live price, fundamentals and results for Emcure Pharmaceuticals on the Univest Screener.
How Did Emcure Pharmaceuticals Perform in Q1 FY27?
Emcure Pharmaceuticals reported Q1 FY27 consolidated revenue of Rs 2,580.4 crore, up 22.8 percent, EBITDA of Rs 508 crore, up 25.8 percent, and net profit of Rs 292.5 crore, up 36.2 percent. EBITDA margin was 19.7 percent and PAT margin 11.3 percent. Together these Q1 FY27 numbers anchor the Emcure Pharmaceuticals share price target.
| Metric | Q1 FY27 | Context |
|---|---|---|
| Revenue from Operations | Rs 2,580.4 crore | Up 22.8% year on year |
| EBITDA | Rs 508 crore | Up 25.8%; margin 19.7% |
| Net Profit | Rs 292.5 crore | Up 36.2%; margin 11.3% |
| International Revenue | Up 34.2% | 58% of total revenue |
| Domestic Revenue | Rs 1,095 crore | 42.4% of revenue |
| Gross Margin | 58.4% | Down 340 basis points on mix |
International growth lowered gross margin but lifted profit, and R&D spend was Rs 90.4 crore, or 3.5 percent of revenue. The company is building uptake of its semaglutide brand Poviztra, planning a Canada semaglutide filing and targeting R&D of 4 to 5 percent of revenue in FY27. The FY27 outlook from management is the main input for these estimates. These numbers sit behind every range in the scenario table above, so they anchor the Emcure Pharmaceuticals share price target.
Why Did Emcure Pharmaceuticals Share Price Rise 44 Percent in a Year?
Emcure shares rose because profit is growing faster than revenue and the international business is scaling. The stock climbed from Rs 1,306.50 in the week of 3 November 2025 to Rs 2,100.70 in the week of 14 September 2026.
It has since eased about 8 percent to Rs 1,933.70 and slipped 1.2 percent on the Q1 results as investors weighed domestic growth quality and the margin mix. The stock is still up about 48 percent from its November low. The Emcure Pharmaceuticals share price target scenarios below account for that move.
Key Catalysts for the Emcure Pharmaceuticals Share Price Target in 2026
4 catalysts matter most for the Emcure Pharmaceuticals share price target, and sector tailwinds in Pharmaceuticals are part of the case. Together they decide whether the base case is reached.
1. International Growth
International revenue grew 34.2 percent and is 58 percent of the total. Overseas growth lifts profit and diversifies earnings. If it plays out, the Emcure Pharmaceuticals share price target moves toward the top of the base range.
2. Semaglutide Opportunity
Poviztra has a new MASH indication and a Canada filing is planned. Obesity and metabolic drugs are a large market. Strength here would support the upper end of the Emcure Pharmaceuticals share price target.
3. Margin Expansion
EBITDA margin rose 50 basis points to 19.7 percent and management targets 70 to 100 basis points for the year. Margin gains lift EPS toward Rs 74. Delivery on this point keeps the Emcure Pharmaceuticals share price target on track.
4. Domestic Stability
The India business delivered Rs 1,095 crore and is stabilising after a slow period. A steady base supports the international push. Better news here would lift the Emcure Pharmaceuticals share price target toward the bull case.
What Are the Key Risks to the Emcure Pharmaceuticals Share Price Target?
The main risks are falling gross margin, domestic growth quality, regulatory issues overseas and a rich valuation. Each can pull the Emcure Pharmaceuticals share price target lower.
Falling Gross Margin
Gross margin fell 340 basis points to 58.4 percent as international mix rose. A further fall would limit profit growth. If it materialises, the Emcure Pharmaceuticals share price target would slip toward the bear case.
Domestic Growth Quality
Investors flagged domestic growth quality after Q1, and the India share fell to 42.4 percent. A weak domestic trend would hit sentiment. This is the main downside risk to the Emcure Pharmaceuticals share price target.
Regulatory Risk
International sales depend on approvals and plant inspections in the US, Europe and Canada. A negative inspection would hurt earnings. A worsening here would cut the Emcure Pharmaceuticals share price target toward the low end of the range.
Rich Valuation
The stock trades at 36.2 times earnings and 7.5 times book. A de-rating toward 24 times FY28 EPS would put the price near Rs 1,490. Watch it closely, because it can pull the Emcure Pharmaceuticals share price target lower quickly.
Emcure Pharmaceuticals Stock Analysis: Support and Resistance Levels for the Share Price Target
Emcure Pharmaceuticals stock analysis on weekly charts shows a range of Rs 1,890 to Rs 2,101 since early September, with the stock near the lower end.
The first support level is Rs 1,907 to Rs 1,919, the low of the week of 28 September and today’s low. Below that, Rs 1,890 is the early-September low, and a weekly close under Rs 1,890 would weaken the base.
The first resistance level is Rs 1,987 to Rs 2,045, the highs of the weeks of 28 and 21 September. Above that, Rs 2,100.70 is the 52-week high. These levels come from weekly price action, are not trade recommendations, and frame the near-term Emcure Pharmaceuticals share price target.
Emcure Pharmaceuticals Share Price Target 2026, 2027 and 2030: Short, Medium and Long Term
Short-Term Emcure Pharmaceuticals Share Price Target (3 to 6 Months)
In the near term the stock is likely to trade between Rs 1,890 and Rs 2,045, from the early-September low to the weekly high. A close above Rs 2,045 would put Rs 2,100 in play, while a break under Rs 1,890 would put Rs 1,830 in play. The Q2 FY27 results are the main trigger. This range anchors the near-term Emcure Pharmaceuticals share price target.
12-Month and 2027 Emcure Pharmaceuticals Share Price Target
The 12-month target price is Rs 1,998 to Rs 2,294, valued on 27 to 31 times FY28 EPS of Rs 74. The range across scenarios runs from Rs 1,488 in the bear case to Rs 2,924 in the bull case.
Long-Term Emcure Pharmaceuticals Share Price Target for FY29 to 2030
For FY29 to 2030 the Univest scenario range is Rs 2,600 to Rs 3,600. This assumes EPS of Rs 100 in FY29 and Rs 120 in FY30 and a multiple of 26 to 30 times. It needs international growth and margin gains to continue. This is the long-term Emcure Pharmaceuticals share price target in the Univest scenarios.
Bull Case and Bear Case for Emcure Pharmaceuticals Share Price Target
Bull Case Rs 2,666 to Rs 2,924
The bull case of Rs 2,666 to Rs 2,924 for the Emcure Pharmaceuticals share price target needs EPS of Rs 86 and the market to pay 31 to 34 times for it. It is +37.9% to +51.2% from the latest price.
Bear Case Rs 1,488 to Rs 1,674
The bear case of Rs 1,488 to Rs 1,674 for the Emcure Pharmaceuticals share price target equals 24 to 27 times FY28 EPS of Rs 62 and sits above the Rs 1,306 low. It is -23.0% to -13.4% from the latest price.
Is Emcure Pharmaceuticals a Good Buy at Rs 1,934? Emcure Pharmaceuticals Buy or Sell View
Whether Emcure Pharmaceuticals is a buy at Rs 1,933.70 depends on horizon and risk appetite. The base case implies 3 to 19 percent from here, the stock trades near its high, and the open question is gross margin. The Emcure Pharmaceuticals share price target range is the starting point for that decision.
Long-term holders may focus on international growth, semaglutide and margin gains, and treat Rs 1,890 as the level to watch. Short-term traders may prefer to wait for a close above Rs 2,045. Check institutional holding in the September quarter filing for signs of accumulation or selling. Consult a SEBI-registered advisor before acting, since this Emcure Pharmaceuticals buy or sell view is educational.
How to Invest in Emcure Pharmaceuticals Shares
Step 1: Check the live price, valuation and the latest Emcure Pharmaceuticals share price target range on the Univest Screener.
Step 2: Open a demat and trading account with a SEBI-registered broker such as Univest before acting on any Emcure Pharmaceuticals share price target.
Step 3: Search for EMCURE on the NSE or 544210 on the BSE in your trading app.
Step 4: Place a limit order near your planned entry and size the position so a fall to Rs 1,488 is bearable.
Step 5: Track international growth, gross margin and Q2 FY27 results and set price alerts on the Univest App to follow any change in the Emcure Pharmaceuticals share price target.
Conclusion
Emcure Pharmaceuticals closed at Rs 1,933.70 against a Univest base case share price target of Rs 1,998 to Rs 2,294, a bull case of Rs 2,666 to Rs 2,924 and a bear case of Rs 1,488 to Rs 1,674. Q1 FY27 delivered a 36.2 percent profit rise to Rs 292.5 crore on 22.8 percent revenue growth, with international revenue up 34.2 percent. The main risks are gross margin, domestic quality and valuation.
The stock is 8 percent below its 52-week high, so the base case implies roughly 3 to 19 percent from here. The triggers to watch are international growth, the Q2 FY27 results and the Rs 1,890 and Rs 2,045 levels. Re-check the Emcure Pharmaceuticals share price target after each quarterly result. Investors with a long horizon and tolerance for volatility can track these triggers, while others may prefer to size positions carefully.
Download the Univest iOS App or Univest Android App to track Emcure Pharmaceuticals live price and get daily stock recommendations.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Emcure Pharmaceuticals Share Price Target 2026
What is the Emcure Pharmaceuticals share price target for 2026?
Ans. The Emcure Pharmaceuticals share price target for 2026 is Rs 1,998 to Rs 2,294 in the Univest base case, with a bull case of Rs 2,666 to Rs 2,924 and a bear case of Rs 1,488 to Rs 1,674. No brokerage price target was available on the sources we track as of 5 October 2026, so every range below is a Univest research scenario. These are estimates and can change after the Q2 FY27 results.
What is the Emcure Pharmaceuticals share price target for 2027?
Ans. The Emcure Pharmaceuticals share price target for 2027 is Rs 1,998 to Rs 2,294 in the base case, valued on 27 to 31 times FY28 EPS of Rs 74. The scenario range runs from Rs 1,488 to Rs 2,924.
Is Emcure Pharmaceuticals a good buy at Rs 1,933.70?
Ans. Whether Emcure Pharmaceuticals is a good buy at Rs 1,933.70 depends on your horizon, risk appetite and how you read the Emcure Pharmaceuticals share price target. Profit is growing 36 percent and margins are improving, but the stock is up 44 percent in a year and trades at about 36 times earnings. Consult a SEBI-registered advisor before investing.
What are the key risks to the Emcure Pharmaceuticals share price target?
Ans. The key risks to the Emcure Pharmaceuticals share price target are falling gross margin, domestic growth quality, regulatory risk and rich valuation. Gross margin fell 340 basis points to 58.4 percent as international mix rose. A further fall would limit profit growth.
What are the key catalysts for the Emcure Pharmaceuticals share price target?
Ans. The key catalysts for the Emcure Pharmaceuticals share price target are international growth, semaglutide opportunity, margin expansion and domestic stability. International revenue grew 34.2 percent and is 58 percent of the total. Overseas growth lifts profit and diversifies earnings.
Where can I track Emcure Pharmaceuticals share price today and Emcure Pharmaceuticals share price target updates?
Ans. You can track the live Emcure Pharmaceuticals share price, results and any change to the Emcure Pharmaceuticals share price target on the Univest Screener and the Univest App. Download the Univest iOS App or Univest Android App for research from SEBI-registered analysts.
What are Emcure Pharmaceuticals’s 52-week high and low?
Ans. Emcure Pharmaceuticals’s 52-week high is Rs 2,100.70 and its 52-week low is Rs 1,306.50, based on weekly NSE data. At Rs 1,933.70 the stock is 7.9 percent below the high and 48.0 percent above the low. Both levels frame the Emcure Pharmaceuticals share price target.
How to buy Emcure Pharmaceuticals shares?
Ans. Open a demat account with a SEBI-registered broker such as Univest, search for EMCURE on the NSE or 544210 on the BSE, and place a limit order near your entry price, using the Emcure Pharmaceuticals share price target range as a guide. Size the position so a fall to Rs 1,488 is bearable, and check the live price on the Univest Screener first.
